About APAC Biotech
APAC Biotech is a company based in Gurugram (India) founded in 2010.. APAC Biotech has raised $991.24 thousand across 1 funding round from investors including Projects Development. APAC Biotech offers products and services including APCEDEN® and LTR-Memvaxraleucel™. APAC Biotech operates in a competitive market with competitors including NexImmune, eTheRNA, Argos Therapeutics, Northwest Biotherapeutics and Dendreon, among others.
- Headquarter Gurugram, India
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Apac Biotech Private Limited
- Date of Incorporation 21 Dec, 2010
- Jurisdiction Delhi, India
-
Annual Revenue
$139.35 K (USD)20.87as on Mar 31, 2023
-
Net Profit
$-375.85 K (USD)-94.76as on Mar 31, 2023
-
EBITDA
$-88.52 K (USD)18.89as on Mar 31, 2023
-
Total Equity Funding
$991.24 K (USD)
in 1 rounds
-
Latest Funding Round
$991.24 K (USD), Seed
Mar 31, 2011
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of APAC Biotech
APAC Biotech offers a comprehensive portfolio of products and services, including APCEDEN® and LTR-Memvaxraleucel™. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Personalized dendritic cell therapy to enhance immune response against cancer.
Reprograms immune cells to treat cancer like a viral infection.
Funding Insights of APAC Biotech
APAC Biotech has successfully raised a total of $991.24K through 1 strategic funding round. The most recent funding activity was a Seed round of $991.24 thousand completed in March 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $991,237
-
First Round
First Round
(31 Mar 2011)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2011 | Amount | Seed - APAC Biotech | Valuation | Projects Development |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in APAC Biotech
APAC Biotech has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Projects Development. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Develops residential and commercial projects with innovative designs in Lebanon.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by APAC Biotech
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - APAC Biotech
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Apac Biotech Comparisons
Competitors of APAC Biotech
APAC Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NexImmune, eTheRNA, Argos Therapeutics, Northwest Biotherapeutics and Dendreon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer, diabetes, and viral diseases are developed.
|
|
| domain | founded_year | HQ Location |
mRNA-based immunotherapies for cancer and infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
An online gambling platform is operated for Tai Xiu games.
|
|
| domain | founded_year | HQ Location |
Dendritic cell-based vaccines for prostate and brain cancers are developed.
|
|
| domain | founded_year | HQ Location |
Autologous dendritic cell immunotherapies are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Dendritic cell immunotherapies for mesothelioma and other cancers are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Apac Biotech
Frequently Asked Questions about APAC Biotech
When was APAC Biotech founded?
APAC Biotech was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Where is APAC Biotech located?
APAC Biotech is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.
Who is the current CEO of APAC Biotech?
Arun Mehra is the current CEO of APAC Biotech.
Is APAC Biotech a funded company?
APAC Biotech is a funded company, having raised a total of $991.24K across 1 funding round to date. The company's 1st funding round was a Seed of $991.24K, raised on Mar 31, 2011.
What is the annual revenue of APAC Biotech?
Annual revenue of APAC Biotech is $139.35K as on Mar 31, 2023.
What does APAC Biotech do?
APAC Biotech was founded in 2010 in Gurugram, India, within the biotechnology sector. Focus is placed on developing autologous monocyte-derived dendritic cell immunotherapy for various cancers. The primary therapy, Apceden, employs patients own monocytes to target cancer-specific dendritic cells. Treatments have been established for colorectal cancer, non-small cell lung carcinoma, ovarian carcinoma, and prostate cancer. Ongoing development targets glioblastoma multiforme and renal cancer.
Who are the top competitors of APAC Biotech?
APAC Biotech's top competitors include eTheRNA, NexImmune and Argos Therapeutics.
What products or services does APAC Biotech offer?
APAC Biotech offers APCEDEN® and LTR-Memvaxraleucel™.
Who are APAC Biotech's investors?
APAC Biotech has 1 investor. Key investors include Projects Development.
What is APAC Biotech's valuation?
The valuation of APAC Biotech is $4.03M as of Mar 2011.